{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T17:48:50Z","timestamp":1788284930940,"version":"build-2803163510"},"reference-count":130,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer J"],"published-print":{"date-parts":[[2020,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Immune checkpoint inhibitor (ICI) therapy is now in widespread clinical use for the treatment of lung cancer. Although patients with autoimmune disease and other comorbidities were excluded from initial clinical trials, emerging real-world experience suggests that these promising treatments may be administered safely to individuals with inactive low-risk autoimmune disease such as rheumatoid arthritis or psoriasis, mild to moderate renal and hepatic dysfunction, and certain chronic viral infections. Considerations for ICI in autoimmune disease populations include exacerbations of the underlying autoimmune disease, increased risk of ICI-induced immune-related adverse events, and potential for compromised efficacy if patients are receiving chronic immunosuppression. Immune checkpoint inhibitor use in higher-risk autoimmune conditions, such as myasthenia gravis or multiple sclerosis, requires careful evaluation on a case-by-case basis. Immune checkpoint inhibitor use in individuals with solid organ transplant carries a substantial risk of organ rejection. Ongoing research into the prediction of ICI efficacy and toxicity may help in patient selection, treatment, and monitoring.<\/jats:p>","DOI":"10.1097\/ppo.0000000000000484","type":"journal-article","created":{"date-parts":[[2020,12,7]],"date-time":"2020-12-07T09:01:50Z","timestamp":1607331710000},"page":"525-536","source":"Crossref","is-referenced-by-count":28,"title":["Immunotherapy Use in Patients With Lung Cancer and Comorbidities"],"prefix":"10.1097","volume":"26","author":[{"given":"Mitchell S.","family":"von Itzstein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amrit S.","family":"Gonugunta","sequence":"additional","affiliation":[{"name":"UT Southwestern Medical School"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen G.","family":"Mayo","sequence":"additional","affiliation":[{"name":"UT Southwestern Health Sciences Digital Library and Learning Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John D.","family":"Minna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David E.","family":"Gerber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"bib1-20230924","doi-asserted-by":"crossref","first-page":"e200423","DOI":"10.1001\/jamanetworkopen.2020.0423","article-title":"Estimation of the percentage of US patients with cancer who are eligible for immune checkpoint inhibitor drugs","volume":"3","year":"2020","journal-title":"JAMA Netw Open"},{"key":"bib2-20230924","first-page":"197","article-title":"Combination immunotherapy development in melanoma","volume":"38","year":"2018","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"suppl 3","key":"bib3-20230924","first-page":"S262","article-title":"Hyperprogressive disease: a distinct effect of immunotherapy?","volume":"11","year":"2019","journal-title":"J Thorac Dis"},{"key":"bib4-20230924","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","year":"2018","journal-title":"N Engl J Med"},{"key":"bib5-20230924","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1200\/JCO.2014.58.3708","article-title":"Overall survival and long-term safety of nivolumab (anti\u2013programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non\u2013small-cell lung cancer","volume":"33","year":"2015","journal-title":"J Clin Oncol"},{"key":"bib6-20230924","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","article-title":"Pembrolizumab versus chemotherapy for previously untreated, PD-L1\u2013expressing, locally advanced or metastatic non\u2013small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial","volume":"393","year":"2019","journal-title":"Lancet"},{"key":"bib7-20230924","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1001\/jamaoncol.2017.4526","article-title":"EGFR-TKI-associated interstitial pneumonitis in nivolumab-treated patients with non\u2013small cell lung cancer","volume":"4","year":"2018","journal-title":"JAMA Oncol"},{"key":"bib8-20230924","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in stage III non\u2013small-cell lung cancer","volume":"377","year":"2017","journal-title":"N Engl J Med"},{"key":"bib9-20230924","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ejca.2019.07.014","article-title":"Haematological immune-related adverse events with immune checkpoint inhibitors, how to manage?","volume":"122","year":"2019","journal-title":"Eur J Cancer"},{"key":"bib10-20230924","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1111\/cas.13932","article-title":"KEYNOTE-025: phase 1b study of pembrolizumab in Japanese patients with previously treated programmed death ligand 1-positive advanced non\u2013small-cell lung cancer","volume":"110","year":"2019","journal-title":"Cancer Sci"},{"key":"bib11-20230924","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1016\/S1470-2045(18)30673-9","article-title":"Avelumab versus docetaxel in patients with platinum-treated advanced non\u2013small-cell lung cancer (JAVELIN lung 200): an open-label, randomised, phase 3 study","volume":"19","year":"2018","journal-title":"Lancet Oncol"},{"key":"bib12-20230924","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/S0140-6736(14)60958-2","article-title":"Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial","volume":"384","year":"2014","journal-title":"Lancet"},{"key":"bib13-20230924","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1056\/NEJMoa1613493","article-title":"First-line nivolumab in stage IV or recurrent non\u2013small-cell lung cancer","volume":"376","year":"2017","journal-title":"N Engl J Med"},{"key":"bib14-20230924","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1111\/1759-7714.12641","article-title":"Generalization and representativeness of phase III immune checkpoint blockade trials in non\u2013small cell lung cancer","volume":"9","year":"2018","journal-title":"Thorac Cancer"},{"key":"bib15-20230924","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1007\/s00408-016-9943-7","article-title":"Selection of patients in ongoing clinical trials on lung cancer","volume":"194","year":"2016","journal-title":"Lung"},{"key":"bib17-20230924","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1007\/s00018-012-0970-0","article-title":"Immune aging and autoimmunity","volume":"69","year":"2012","journal-title":"Cell Mol Life Sci"},{"key":"bib18-20230924","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1053\/j.ackd.2010.05.002","article-title":"The aging kidney: physiological changes","volume":"17","year":"2010","journal-title":"Adv Chronic Kidney Dis"},{"key":"bib19-20230924","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1513\/pats.200809-100TH","article-title":"Smoking and lung cancer: the role of inflammation","volume":"5","year":"2008","journal-title":"Proc Am Thorac Soc"},{"key":"bib20-20230924","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1080\/1744666X.2018.1473035","article-title":"Cigarette smoking and the pathogenesis of systemic lupus erythematosus","volume":"14","year":"2018","journal-title":"Expert Rev Clin Immunol"},{"key":"bib21-20230924","doi-asserted-by":"crossref","first-page":"22279","DOI":"10.3390\/ijms151222279","article-title":"Smoking and rheumatoid arthritis","volume":"15","year":"2014","journal-title":"Int J Mol Sci"},{"key":"bib22-20230924","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1016\/j.jtho.2018.08.2035","article-title":"Pneumonitis in non\u2013small cell lung cancer patients receiving immune checkpoint immunotherapy: incidence and risk factors","volume":"13","year":"2018","journal-title":"J Thorac Oncol"},{"key":"bib23-20230924","doi-asserted-by":"crossref","first-page":"e1911519","DOI":"10.1001\/jamanetworkopen.2019.11519","article-title":"Variation in the assessment of immune-related adverse event occurrence, grade, and timing in patients receiving immune checkpoint inhibitors","volume":"2","year":"2019","journal-title":"JAMA Netw Open"},{"key":"bib24-20230924","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1186\/1756-0500-7-264","article-title":"The clinical case report: a review of its merits and limitations","volume":"7","year":"2014","journal-title":"BMC Res Notes"},{"key":"bib25-20230924","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1001\/jamaoncol.2016.2238","article-title":"Prevalence of autoimmune disease among patients with lung cancer: implications for immunotherapy treatment options","volume":"2","year":"2016","journal-title":"JAMA Oncol"},{"key":"bib26-20230924","doi-asserted-by":"crossref","first-page":"3851","DOI":"10.1200\/JCO.2016.72.1985","article-title":"Safety and efficacy of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma: the CheckMate 016 study","volume":"35","year":"2017","journal-title":"J Clin Oncol"},{"key":"bib27-20230924","doi-asserted-by":"crossref","first-page":"3924","DOI":"10.1200\/JCO.2017.74.3062","article-title":"Nivolumab versus docetaxel in previously treated patients with advanced non\u2013small-cell lung cancer: two-year outcomes from two randomized, open-label, phase III trials (CheckMate 017 and CheckMate 057)","volume":"35","year":"2017","journal-title":"J Clin Oncol"},{"key":"bib28-20230924","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/S1470-2045(17)30065-7","article-title":"Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial","volume":"18","year":"2017","journal-title":"Lancet Oncol"},{"key":"bib29-20230924","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jaut.2006.09.001","article-title":"Autoantibody profiling to identify individuals at risk for systemic lupus erythematosus","volume":"27","year":"2006","journal-title":"J Autoimmun"},{"key":"bib30-20230924","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40425-018-0484-x","article-title":"Complete response of metastatic melanoma in a patient with Crohn's disease simultaneously receiving anti-\u03b14\u03b27 and anti-PD1 antibodies","volume":"7","year":"2019","journal-title":"J Immunother Cancer"},{"key":"bib31-20230924","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s13045-016-0309-7","article-title":"Selective inhibition of autoimmune exacerbation while preserving the anti-tumor clinical benefit using IL-6 blockade in a patient with advanced melanoma and Crohn's disease: a case report","volume":"9","year":"2016","journal-title":"J Hematol Oncol"},{"key":"bib32-20230924","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s00262-017-1962-6","article-title":"Vedolizumab treatment for immune checkpoint inhibitor\u2013induced enterocolitis","volume":"66","year":"2017","journal-title":"Cancer Immunol Immunother"},{"key":"bib33-20230924","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1007\/s00262-014-1607-y","article-title":"Successful treatment with ipilimumab and interleukin-2 in two patients with metastatic melanoma and systemic autoimmune disease","volume":"63","year":"2014","journal-title":"Cancer Immunol Immunother"},{"key":"bib34-20230924","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1200\/JCO.2017.77.0305","article-title":"Safety of programmed death-1 pathway inhibitors among patients with non\u2013small-cell lung cancer and preexisting autoimmune disorders","volume":"36","year":"2018","journal-title":"J Clin Oncol"},{"key":"bib35-20230924","first-page":"1","article-title":"Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders","year":"2015","journal-title":"JAMA Oncol"},{"key":"bib36-20230924","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s00262-018-2134-z","article-title":"Ipilimumab in metastatic melanoma patients with pre-existing autoimmune disorders","volume":"67","year":"2018","journal-title":"Cancer Immunol Immunother"},{"key":"bib37-20230924","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1093\/annonc\/mdw443","article-title":"Anti\u2013PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab","volume":"28","year":"2017","journal-title":"Ann Oncol"},{"key":"bib38-20230924","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ejca.2016.12.038","article-title":"Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity","volume":"75","year":"2017","journal-title":"Eur J Cancer"},{"key":"bib39-20230924","doi-asserted-by":"crossref","first-page":"e327","DOI":"10.1634\/theoncologist.2018-0618","article-title":"Clinical outcomes of patients with advanced cancer and pre-existing autoimmune diseases treated with anti\u2013programmed death-1 immunotherapy: a real-world transverse study","volume":"24","year":"2019","journal-title":"Oncologist"},{"key":"bib40-20230924","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1002\/art.41068","article-title":"Safety and efficacy of immune checkpoint inhibitors in patients with cancer and preexisting autoimmune disease: a nationwide, multicenter cohort study","volume":"71","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"bib41-20230924","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1186\/s40425-019-0774-y","article-title":"Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature","volume":"7","year":"2019","journal-title":"J Immunother Cancer"},{"key":"bib42-20230924","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s40425-014-0035-z","article-title":"Ipilimumab in patients with melanoma and autoimmune disease","volume":"2","year":"2014","journal-title":"J Immunother Cancer"},{"key":"bib43-20230924","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1177\/1352458514549403","article-title":"Severe relapse in a multiple sclerosis patient associated with ipilimumab treatment of melanoma","volume":"21","year":"2015","journal-title":"Mult Scler"},{"key":"bib44-20230924","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ejca.2017.12.008","article-title":"Safety and efficacy of anti\u2013programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease","volume":"91","year":"2018","journal-title":"Eur J Cancer"},{"key":"bib45-20230924","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1093\/annonc\/mdw056","article-title":"The use of ipilimumab in patients with rheumatoid arthritis and metastatic melanoma","volume":"27","year":"2016","journal-title":"Ann Oncol"},{"key":"bib46-20230924","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1097\/CMR.0000000000000387","article-title":"The safety of pembrolizumab in metastatic melanoma and rheumatoid arthritis","volume":"27","year":"2017","journal-title":"Melanoma Res"},{"key":"bib47-20230924","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1002\/art.40397","article-title":"Brief report: cancer immunotherapy in patients with preexisting rheumatic disease: the Mayo Clinic experience","volume":"70","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"bib48-20230924","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s40425-016-0123-3","article-title":"Disease stabilization with pembrolizumab for metastatic acral melanoma in the setting of autoimmune bullous pemphigoid","volume":"4","year":"2016","journal-title":"J Immunother Cancer"},{"key":"bib49-20230924","doi-asserted-by":"crossref","first-page":"e403","DOI":"10.3747\/co.25.4047","article-title":"Predictors of immunotherapy-induced immune-related adverse events","volume":"25","year":"2018","journal-title":"Curr Oncol"},{"key":"bib50-20230924","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.lungcan.2019.01.014","article-title":"Safety and efficacy of PD-1 inhibitors in non\u2013small cell lung cancer patients positive for antinuclear antibodies","volume":"130","year":"2019","journal-title":"Lung Cancer"},{"key":"bib51-20230924","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1007\/s12094-019-02060-8","article-title":"Multiple sclerosis outcomes after cancer immunotherapy","volume":"21","year":"2019","journal-title":"Clin Transl Oncol"},{"key":"bib52-20230924","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.2169\/internalmedicine.3018-19","article-title":"Non\u2013small cell lung cancer treated by an anti\u2013programmed cell death-1 antibody without a flare-up of preexisting granulomatosis with Polyangiitis","volume":"58","year":"2019","journal-title":"Intern Med"},{"key":"bib53-20230924","doi-asserted-by":"crossref","first-page":"838","DOI":"10.4065\/mcp.2010.0099","article-title":"Paraneoplastic syndromes: an approach to diagnosis and treatment","volume":"85","year":"2010","journal-title":"Mayo Clin Proc"},{"key":"bib54-20230924","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","article-title":"Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial","volume":"394","year":"2019","journal-title":"Lancet"},{"key":"bib55-20230924","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","article-title":"First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer","volume":"379","year":"2018","journal-title":"N Engl J Med"},{"key":"bib56-20230924","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1200\/JCO.2017.77.3184","article-title":"Pembrolizumab for patients with refractory or relapsed thymic epithelial tumor: an open-label phase II trial","volume":"37","year":"2019","journal-title":"J Clin Oncol"},{"key":"bib57-20230924","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S1470-2045(18)30062-7","article-title":"Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study","volume":"19","year":"2018","journal-title":"Lancet Oncol"},{"issue":"suppl 15","key":"bib58-20230924","first-page":"347","article-title":"Safety and clinical activity of anti-programmed death-ligand 1 (PD-L1) antibody (ab) avelumab (MSB0010718C) in advanced thymic epithelial tumors (TETs) [published online May 20, 2016]","volume":"34","year":"2016","journal-title":"J Clin Oncol"},{"key":"bib59-20230924","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s11060-009-0057-4","article-title":"The role of steroids in the management of brain metastases: a systematic review and evidence-based clinical practice guideline","volume":"96","year":"2010","journal-title":"J Neurooncol"},{"key":"bib60-20230924","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1200\/JCO.2007.15.5796","article-title":"Interventions for alleviating cancer-related dyspnea: a systematic review","volume":"26","year":"2008","journal-title":"J Clin Oncol"},{"key":"bib61-20230924","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/bs.ircmb.2018.05.009","article-title":"Impact of immunosuppressive drugs on the metabolism of T cells","volume":"341","year":"2018","journal-title":"Int Rev Cell Mol Biol"},{"key":"bib62-20230924","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.celrep.2014.04.041","article-title":"How steroids steer T cells","volume":"7","year":"2014","journal-title":"Cell Rep"},{"key":"bib63-20230924","first-page":"5857","article-title":"Predictive factors for poor progression-free survival in patients with non\u2013small cell lung cancer treated with nivolumab","volume":"37","year":"2017","journal-title":"Anticancer Res"},{"key":"bib64-20230924","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1200\/JCO.2018.79.0006","article-title":"Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non\u2013small-cell lung cancer","volume":"36","year":"2018","journal-title":"J Clin Oncol"},{"key":"bib65-20230924","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1200\/JCO.19.00189","article-title":"Immune checkpoint inhibitor outcomes for patients with non\u2013small-cell lung cancer receiving baseline corticosteroids for palliative versus nonpalliative indications","volume":"37","year":"2019","journal-title":"J Clin Oncol"},{"key":"bib66-20230924","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1200\/JCO.2015.60.8448","article-title":"Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center","volume":"33","year":"2015","journal-title":"J Clin Oncol"},{"key":"bib67-20230924","article-title":"Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: review of the literature and personalized risk-based prevention strategy","year":"2020","journal-title":"Ann Oncol"},{"key":"bib68-20230924","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1016\/j.jaad.2019.07.005","article-title":"Immune checkpoint inhibitor therapy in solid organ transplant recipients: a patient-centered systematic review","volume":"82","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"bib69-20230924","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1200\/JCO.2017.74.4102","article-title":"Modernizing clinical trial eligibility criteria: recommendations of the American Society of Clinical Oncology\u2014Friends of Cancer Research Organ Dysfunction, Prior or Concurrent Malignancy, and Comorbidities Working Group","volume":"35","year":"2017","journal-title":"J Clin Oncol"},{"key":"bib70-20230924","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1007\/s40262-019-00748-2","article-title":"Clinical pharmacokinetics and pharmacodynamics of immune checkpoint inhibitors","volume":"58","year":"2019","journal-title":"Clin Pharmacokinet"},{"key":"bib71-20230924","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s11912-019-0852-9","article-title":"Poor-performance status assessment of patients with non\u2013small cell lung cancer remains vague and blurred in the immunotherapy era","volume":"21","year":"2019","journal-title":"Curr Oncol Rep"},{"key":"bib72-20230924","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s40425-016-0166-5","article-title":"Safety and efficacy of anti\u2013PD-1 in patients with baseline cardiac, renal, or hepatic dysfunction","volume":"4","year":"2016","journal-title":"J Immunother Cancer"},{"key":"bib73-20230924","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.lungcan.2018.10.001","article-title":"Pre-existing pulmonary fibrosis is a risk factor for anti\u2013PD-1\u2013related pneumonitis in patients with non\u2013small cell lung cancer: a retrospective analysis","volume":"125","year":"2018","journal-title":"Lung Cancer"},{"issue":"suppl 15","key":"bib74-20230924","article-title":"Pre-existing interstitial lung abnormalities are risk factors for immune checkpoint inhibitor\u2013induced interstitial lung disease in non-NSCLC cancers [published online May 25, 2020]","volume":"38","year":"2020","journal-title":"J Clin Oncol"},{"key":"bib75-20230924","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.resinv.2019.05.002","article-title":"Pre-existing interstitial lung abnormalities are risk factors for immune checkpoint inhibitor\u2013induced interstitial lung disease in non\u2013small cell lung cancer","volume":"57","year":"2019","journal-title":"Respir Investig"},{"key":"bib76-20230924","doi-asserted-by":"crossref","first-page":"13773","DOI":"10.1038\/s41598-020-70743-2","article-title":"Risk factors of immune checkpoint inhibitor\u2013related interstitial lung disease in patients with lung cancer: a single-institution retrospective study","volume":"10","year":"2020","journal-title":"Sci Rep"},{"key":"bib77-20230924","doi-asserted-by":"crossref","first-page":"170045","DOI":"10.1183\/16000617.0045-2017","article-title":"Immune checkpoints in chronic obstructive pulmonary disease","volume":"26","year":"2017","journal-title":"Eur Respir Rev"},{"key":"bib78-20230924","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.2147\/COPD.S214610","article-title":"Effect of PD-1 inhibitor on exhaled nitric oxide and pulmonary function in non\u2013small cell lung cancer patients with and without COPD","volume":"14","year":"2019","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"bib79-20230924","first-page":"6","article-title":"Managing cardiotoxicity associated with immune checkpoint inhibitors","volume":"5","year":"2019","journal-title":"Chronic Dis Transl Med"},{"issue":"suppl 35","key":"bib80-20230924","first-page":"S4323","article-title":"Heart failure in cancer: role of checkpoint inhibitors","volume":"10","year":"2018","journal-title":"J Thorac Dis"},{"key":"bib81-20230924","doi-asserted-by":"crossref","first-page":"972","DOI":"10.3389\/fphar.2020.00972","article-title":"How to monitor cardiac complications of immune checkpoint inhibitor therapy","volume":"11","year":"2020","journal-title":"Front Pharmacol"},{"key":"bib82-20230924","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1111\/apt.15449","article-title":"Review article: immune checkpoint inhibitors and the liver, from therapeutic efficacy to side effects","volume":"50","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"bib83-20230924","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1053\/j.ajkd.2019.03.433","article-title":"Kidney complications of immune checkpoint inhibitors: a review","volume":"74","year":"2019","journal-title":"Am J Kidney Dis"},{"key":"bib84-20230924","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1681\/ASN.2019070676","article-title":"Clinical features and outcomes of immune checkpoint inhibitor\u2013associated AKI: a multicenter study","volume":"31","year":"2020","journal-title":"J Am Soc Nephrol"},{"key":"bib85-20230924","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/JTO.0b013e3181622c17","article-title":"Prevalence of poor performance status in lung cancer patients: implications for research","volume":"3","year":"2008","journal-title":"J Thorac Oncol"},{"key":"bib86-20230924","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ejca.2019.11.019","article-title":"CheckMate 171: a phase 2 trial of nivolumab in patients with previously treated advanced squamous non\u2013small cell lung cancer, including ECOG PS 2 and elderly populations","volume":"127","year":"2020","journal-title":"Eur J Cancer"},{"key":"bib87-20230924","article-title":"Nivolumab in previously treated patients with metastatic squamous NSCLC: results of a European single-arm, phase 2 trial (CheckMate 171) including patients aged 70 years and with poor performance status","volume":"28","year":"2017","journal-title":"Ann Oncol"},{"key":"bib88-20230924","doi-asserted-by":"crossref","first-page":"S1287","DOI":"10.1016\/j.jtho.2016.11.1821","article-title":"Is nivolumab safe and effective in elderly and PS2 patients with non\u2013small cell lung cancer (NSCLC)? Results of CheckMate 153","volume":"12","year":"2017","journal-title":"J Thorac Oncol"},{"key":"bib89-20230924","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1007\/s12032-018-1194-4","article-title":"Patient performance status and cancer immunotherapy efficacy: a meta-analysis","volume":"35","year":"2018","journal-title":"Med Oncol"},{"key":"bib90-20230924","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1001\/jamaoncol.2019.2187","article-title":"Five-year survival and correlates among patients with advanced melanoma, renal cell carcinoma, or non\u2013small cell lung cancer treated with Nivolumab","volume":"5","year":"2019","journal-title":"JAMA Oncol"},{"key":"bib91-20230924","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.lungcan.2018.02.017","article-title":"Efficacy and safety of nivolumab in previously treated patients with non\u2013small cell lung cancer: a multicenter retrospective cohort study","volume":"119","year":"2018","journal-title":"Lung Cancer"},{"key":"bib92-20230924","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1016\/j.jtho.2018.04.025","article-title":"Italian nivolumab expanded access program in nonsquamous non\u2013small cell lung cancer patients: results in never-smokers and EGFR-mutant patients","volume":"13","year":"2018","journal-title":"J Thorac Oncol"},{"key":"bib93-20230924","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1080\/1120009X.2018.1551753","article-title":"Efficacy and safety of nivolumab in patients with non\u2013small cell lung cancer: a retrospective study in clinical practice","volume":"31","year":"2019","journal-title":"J Chemother"},{"key":"bib94-20230924","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s11523-019-00679-9","article-title":"Therapy line and associated predictors of response to PD-1\/PD-L1\u2013inhibitor monotherapy in advanced non\u2013small-cell lung cancer: a retrospective bi-centric cohort study","volume":"14","year":"2019","journal-title":"Target Oncol"},{"key":"bib95-20230924","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1007\/s00432-019-02899-y","article-title":"Comprehensive analysis of the characteristics and treatment outcomes of patients with non\u2013small cell lung cancer treated with anti\u2013PD-1 therapy in real-world practice","volume":"145","year":"2019","journal-title":"J Cancer Res Clin Oncol"},{"key":"bib96-20230924","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.lungcan.2019.05.005","article-title":"Pembrolizumab for advanced nonsmall cell lung cancer: efficacy and safety in everyday clinical practice","volume":"133","year":"2019","journal-title":"Lung Cancer"},{"key":"bib97-20230924","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1200\/JCO.18.02118","article-title":"Immunotherapy in non\u2013small-cell lung cancer patients with performance status 2: clinical decision making with scant evidence","volume":"37","year":"2019","journal-title":"J Clin Oncol"},{"key":"bib98-20230924","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1111\/jgs.15750","article-title":"Immune checkpoint inhibitors in real-world treatment of older adults with non\u2013small cell lung cancer","volume":"67","year":"2019","journal-title":"J Am Geriatr Soc"},{"key":"bib99-20230924","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.jtho.2018.11.011","article-title":"Impact of age on outcomes with immunotherapy in patients with non\u2013small cell lung cancer","volume":"14","year":"2019","journal-title":"J Thorac Oncol"},{"key":"bib100-20230924","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.jgo.2019.09.011","article-title":"Real life safety and effectiveness of nivolumab in older patients with non\u2013small cell lung cancer: results from the Belgian compassionate use program","volume":"11","year":"2020","journal-title":"J Geriatr Oncol"},{"key":"bib101-20230924","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.lungcan.2019.08.030","article-title":"Efficacy and safety of immunotherapy in elderly patients with non\u2013small cell lung cancer","volume":"137","year":"2019","journal-title":"Lung Cancer"},{"key":"bib102-20230924","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1053\/j.seminoncol.2018.08.007","article-title":"FDA analyses of survival in older adults with metastatic non\u2013small cell lung cancer in controlled trials of PD-1\/PD-L1 blocking antibodies","volume":"45","year":"2018","journal-title":"Semin Oncol"},{"key":"bib103-20230924","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1053\/j.seminoncol.2018.08.006","article-title":"Aging, immune senescence, and immunotherapy: a comprehensive review","volume":"45","year":"2018","journal-title":"Semin Oncol"},{"key":"bib104-20230924","doi-asserted-by":"crossref","first-page":"F13","DOI":"10.1097\/QAD.0000000000002298","article-title":"Immunotherapy for cancer in people living with HIV: safety with an efficacy signal from the series in real life experience","volume":"33","year":"2019","journal-title":"AIDS"},{"key":"bib105-20230924","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.jtho.2018.03.031","article-title":"Safety and efficacy of PD-1 inhibitors among HIV-positive patients with non\u2013small cell lung cancer","volume":"13","year":"2018","journal-title":"J Thorac Oncol"},{"key":"bib106-20230924","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1093\/annonc\/mdx817","article-title":"PD-1 blockade in HIV-infected patients with lung cancer: a new challenge or already a strategy?","volume":"29","year":"2018","journal-title":"Ann Oncol"},{"key":"bib107-20230924","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1186\/s40425-019-0771-1","article-title":"Safety and efficacy of immune checkpoint inhibitors (ICIs) in cancer patients with HIV, hepatitis B, or hepatitis C viral infection","volume":"7","year":"2019","journal-title":"J Immunother Cancer"},{"key":"bib108-20230924","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1097\/CJI.0000000000000240","article-title":"Nivolumab treatment for cancers in the HIV-infected population","volume":"41","year":"2018","journal-title":"J Immunother"},{"key":"bib109-20230924","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1001\/jamaoncol.2018.6737","article-title":"Safety and efficacy of immune checkpoint inhibitor therapy in patients with HIV infection and advanced-stage cancer: a systematic review","volume":"5","year":"2019","journal-title":"JAMA Oncol"},{"key":"bib110-20230924","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1200\/JOP.19.00754","article-title":"Safety and efficacy of immune checkpoint inhibitors in patients with cancer living with HIV: a perspective on recent Progress and future needs","volume":"16","year":"2020","journal-title":"JCO Oncol Pract"},{"key":"bib111-20230924","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/CMR.0000000000000434","article-title":"Safety and efficacy of anti\u2013PD-1 therapy for metastatic melanoma and non\u2013small-cell lung cancer in patients with viral hepatitis: a case series","volume":"28","year":"2018","journal-title":"Melanoma Res"},{"key":"bib112-20230924","doi-asserted-by":"crossref","first-page":"e19013","DOI":"10.1097\/MD.0000000000019013","article-title":"Safety and efficacy of immune checkpoint inhibitors in patients with HBV\/HCV infection and advanced-stage cancer: a systematic review","volume":"99","year":"2020","journal-title":"Medicine (Baltimore)"},{"key":"bib113-20230924","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1111\/1759-7714.13153","article-title":"Worse lung cancer outcome in patients with lower respiratory tract infection confirmed at time of diagnosis","volume":"10","year":"2019","journal-title":"Thorac Cancer"},{"key":"bib114-20230924","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.3389\/fimmu.2018.02640","article-title":"Respiratory viral infection-induced microbiome alterations and secondary bacterial pneumonia","volume":"9","year":"2018","journal-title":"Front Immunol"},{"key":"bib115-20230924","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/s41591-019-0377-7","article-title":"The microbiome, cancer, and cancer therapy","volume":"25","year":"2019","journal-title":"Nat Med"},{"key":"bib116-20230924","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1093\/annonc\/mdx108","article-title":"Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab","volume":"28","year":"2017","journal-title":"Ann Oncol"},{"key":"bib117-20230924","doi-asserted-by":"crossref","first-page":"10391","DOI":"10.1038\/ncomms10391","article-title":"Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade\u2013induced colitis","volume":"7","year":"2016","journal-title":"Nat Commun"},{"key":"bib118-20230924","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.jtho.2020.05.001","article-title":"Treatment guidance for patients with lung cancer during the coronavirus 2019 pandemic","volume":"15","year":"2020","journal-title":"J Thorac Oncol"},{"key":"bib119-20230924","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.annonc.2020.04.002","article-title":"Testing for COVID-19 in lung cancer patients","volume":"31","year":"2020","journal-title":"Ann Oncol"},{"key":"bib120-20230924","doi-asserted-by":"crossref","first-page":"269","DOI":"10.2217\/imt-2020-0067","article-title":"Controversies about COVID-19 and anticancer treatment with immune checkpoint inhibitors","volume":"12","year":"2020","journal-title":"Immunotherapy"},{"key":"bib121-20230924","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/S1470-2045(20)30314-4","article-title":"COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study","volume":"21","year":"2020","journal-title":"Lancet Oncol"},{"issue":"suppl 4","key":"bib122-20230924","first-page":"iv192","article-title":"Metastatic non\u2013small cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"29","year":"2018","journal-title":"Ann Oncol"},{"key":"bib123-20230924","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1200\/JCO.19.03022","article-title":"Therapy for stage IV non\u2013small-cell lung cancer without driver alterations: ASCO and OH (CCO) joint guideline update","volume":"38","year":"2020","journal-title":"J Clin Oncol"},{"key":"bib124-20230924","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.6004\/jnccn.2019.0059","article-title":"NCCN guidelines insights: non\u2013small cell lung cancer, version 1.2020","volume":"17","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"key":"bib125-20230924","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1093\/clinchem\/hvaa081","article-title":"Investigational biomarkers for checkpoint inhibitor immune\u2013related adverse event prediction and diagnosis","volume":"66","year":"2020","journal-title":"Clin Chem"},{"key":"bib126-20230924","doi-asserted-by":"crossref","first-page":"e1242","DOI":"10.1634\/theoncologist.2019-0911","article-title":"Statin intolerance, anti-HMGCR antibodies, and immune checkpoint inhibitor\u2013associated myositis: a \u201ctwo-hit\u201d autoimmune toxicity or clinical predisposition?","volume":"25","year":"2020","journal-title":"Oncologist"},{"key":"bib127-20230924","doi-asserted-by":"crossref","first-page":"e753","DOI":"10.1634\/theoncologist.2019-0666","article-title":"Late-onset immunotherapy toxicity and delayed autoantibody changes: checkpoint inhibitor\u2013induced Raynaud's-like phenomenon","volume":"25","year":"2020","journal-title":"Oncologist"},{"key":"bib128-20230924","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1038\/s41591-018-0157-9","article-title":"Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma","volume":"24","year":"2018","journal-title":"Nat Med"},{"key":"bib129-20230924","doi-asserted-by":"crossref","first-page":"166","DOI":"10.21037\/atm.2018.03.28","article-title":"Financial toxicity and implications for cancer care in the era of molecular and immune therapies","volume":"6","year":"2018","journal-title":"Ann Transl Med"},{"key":"bib130-20230924","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s40425-018-0442-7","article-title":"A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors","volume":"6","year":"2018","journal-title":"J Immunother Cancer"},{"key":"bib131-20230924","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1002\/cncr.31795","article-title":"Cost-effectiveness of immune checkpoint inhibitors for microsatellite instability-high\/mismatch repair\u2013deficient metastatic colorectal cancer","volume":"125","year":"2019","journal-title":"Cancer"}],"container-title":["The Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PPO.0000000000000484","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T01:21:09Z","timestamp":1695518469000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PPO.0000000000000484"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":130,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/ppo.0000000000000484","relation":{},"ISSN":["1540-336X","1528-9117"],"issn-type":[{"value":"1540-336X","type":"electronic"},{"value":"1528-9117","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]}}}